| h-38292315 | Metabolic Reprogramming via Microglial Glycolysis Inhibition | 0.67 | 0.40 | HK2 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-691b42f1 |
| h-var-c46786d2ab | Astrocytic-Mediated Tau Clearance Dysfunction via TREM2 Signaling | 0.67 | 0.71 | TREM2 | proposed | 2026-04-12 | SDA-2026-04-03-26abc5e5f9f2 |
| h-baba5269 | Partial Neuronal Reprogramming via Modified Yamanaka Cocktail | 0.67 | 0.50 | OCT4 | debated | 2026-04-02 | SDA-2026-04-04-gap-epigenetic-reprog-b685190e |
| h-110fecd1f6 | Seed match plus local RNA structure jointly determine lncRNA-0021 binding to mmu | 0.67 | 0.61 | lncRNA-0021 | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-150509-76c40dac-debate |
| h-f714b6f6aa | OPC exhaustion and failed remyelination in progressive multiple sclerosis | 0.67 | 0.68 | PDGFRA; CSPG4; CDKN2A; CDKN1A; GATA3 | proposed | 2026-04-30 | SDA-2026-04-30-gap-test-20260425-224949 |
| h-c2452f6e0e | Mitophagy and NAD pathway enhancement in sporadic Parkinson's disease | 0.67 | 0.66 | PINK1; PRKN | proposed | 2026-04-29 | SDA-2026-04-29-gap-test-20260425-224949 |
| h-6c347bffd7 | TREM2 Agonism to Promote Neuroprotective Microglial Phenotype in Alzheimer's Dis | 0.67 | 0.78 | TREM2 | proposed | 2026-04-28 | SDA-2026-04-28-gap-test-20260425-224949 |
| h-96aac98502 | Adaptive Closed-Loop Gamma/Theta-Gamma Entrainment of Entorhinal-Hippocampal Cir | 0.67 | 0.72 | N/A (electrophysiologic network target) | proposed | 2026-04-28 | SRB-2026-04-28-h-var-b7e4505525 |
| h-9dc6fc2bb1 | APOE4-Targeted Microglial Reprogramming via Anti-APOE4 Antibodies | 0.67 | 0.80 | APOE | proposed | 2026-04-26 | test-hypothesis-fixtures-v1 |
| h-78b2af94ab | Leaky Gut LPS Translocation Activates Systemic TLR4/MyD88 Signaling, Driving CNS | 0.67 | 0.78 | TLR4, MyD88, IRAK4, CCL2, CCR2, ZO-1 (TJP1) | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260425-225305 |
| h-a962a518d3 | FABP5/7 Inhibition (H2): Lipid Relay Interruption | 0.67 | 0.65 | FABP5/FABP7 (fatty acid binding proteins) | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-180918-962b1ada-debate |
| h-32b63761ed | Fyn-anchored dendritic tau/NMDAR signaling persists after transient Aβ exposure | 0.67 | 0.71 | MAPT,FYN,DLG4,GRIN2B | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-98a600b3ed |
| h-85b51a8f58 | Microglial TREM2 state determines whether C1q-tagged substrates are cleared adap | 0.67 | 0.71 | TREM2,TYROBP,C1QA,C1QB,C1QC,C3 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-afba1a80bd |
| h-ca6480add4 | Physiological SCFAs may confer indirect anti-synuclein benefit through an entero | 0.67 | 0.60 | FFAR2/FFAR3/GLP1R | proposed | 2026-04-24 | SDA-2026-04-25-gapdebate-18cce7b525 |
| h-c9b96e0e3b | Rab12 may better report chronic lysosomal stress biology than Rab10 in G2019S co | 0.67 | 0.72 | RAB12 | proposed | 2026-04-24 | SDA-2026-04-25-gapdebate-9180363b7c |
| h-8af27bf934 | LPS-primed microglial trained immunity establishes persistent H3K4me3 landscapes | 0.67 | 0.72 | NLRP3, H3K4me3 writers (MLL3/4, SETD1A), H3K27ac (EP300/CREB | proposed | 2026-04-22 | SDA-2026-04-02-gap-synaptic-pruning-microglia |
| h-79a0d74450 | H1: TET-Mediated 5-Hydroxymethylcytosine Loss Drives Neuronal Transcriptomic Dri | 0.67 | 0.72 | TET1, TET2, 5-hydroxymethylcytosine (5hmC) | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-120802 |
| h-45bc32028c | Restore AQP4 Perivascular Polarization by Stabilizing DAPC/SNTA1/DAG1 Anchoring | 0.67 | 0.72 | AQP4, SNTA1, DAG1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2 |
| h-080e9babfd | AQP4-Dependent Astrocyte Swelling Exacerbates Excitotoxic Neuronal Death via Dys | 0.67 | 0.72 | AQP4; SLC1A2 (GLT-1) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e |
| h-bc161bb779 | OPTN/TBK1 mutations create selective vulnerability by blocking PINK1-Parkin-inde | 0.67 | 0.70 | OPTN | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062212-6777e5dd |
| h-ded1734f | Dissociating SCFA's Dual Signaling Through GPR43/GPR41 Biased Agonism | 0.67 | 0.72 | FFAR2, FFAR3, NLRP3 | promoted | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113021-6fbc6da4 |
| h-76ea1f28 | TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulation | 0.67 | 0.82 | TREM2/ACAT1/LXR | promoted | 2026-04-15 | SDA-2026-04-15-gap-debate-20260410-112522-57d1cc4f |
| h-a4e259e0 | Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Com | 0.67 | 0.50 | CHRNA7 | proposed | 2026-04-02 | SDA-2026-04-01-gap-20260401-225149 |
| h-immunity-c3bc272f | C1q-TREM2 Competition for Phosphatidylserine as Pruning Checkpoint | 0.67 | 0.68 | C1QA, C1QB, TREM2, PSR | open | 2026-04-24 | |
| h-seaad-v4-29e81bbc | Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupling | 0.67 | 0.50 | SLC16A1 | debated | 2026-04-02 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-23b94ed8 | Locus Coeruleus-Hippocampal Circuit Protection | 0.67 | 0.70 | MAPT | promoted | 2026-04-04 | SDA-2026-04-03-26abc5e5f9f2 |
| h-fee0ce2ca5 | TREM2 Agonism Has Narrow Early-Window at DAM1→DAM2 Transition Checkpoint | 0.67 | 0.60 | TREM2, SYK signaling axis | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-7a6cf14e |
| h-077e448d | LXRβ-Selective Agonism to Simultaneously Enhance APOE Lipidation and Reduce Micr | 0.67 | 0.70 | LXRβ (NR1H2) | proposed | 2026-04-25 | SDA-2026-04-16-frontier-lipidomics-dcdbc360 |
| h-9eae33ba | Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation | 0.67 | 0.30 | KCNK2 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-0791836f | Mitochondrial-Lysosomal Contact Site Engineering | 0.67 | 0.68 | RAB7A | debated | 2026-04-02 | sda-2026-04-01-gap-011 |
| h-c5698ce3 | White Matter Vulnerability Prevention via Oligodendrocyte Protection | 0.67 | 0.75 | CXCL10 | promoted | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-var-e0e82ff2e2 | TREM2-Mediated Cholesterol Dysregulation in Microglial Senescence | 0.67 | 0.72 | CYP46A1 | promoted | 2026-04-07 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-7d4a24d3 | Lipid Droplet Dynamics as Phenotype Switches | 0.67 | 0.35 | DGAT1 and SOAT1 | debated | 2026-04-02 | sda-2026-04-01-gap-007 |
| h-155f0b0c | LRRK2 Volume Sensor Hijacking Drives Metabolic Dysregulation via SIRT1/PGC1α Sup | 0.67 | 0.42 | LRRK2 | proposed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867 |
| h-var-6a0893ffb6 | Glymphatic-Cholinergic Tau Clearance Cascade | 0.67 | 0.65 | MAPT | proposed | 2026-04-07 | SDA-2026-04-03-26abc5e5f9f2 |
| h-6ce4884a | GAP43-mediated tunneling nanotube stabilization enhances neuroprotective mitocho | 0.67 | 0.35 | GAP43 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-89432b95 |
| h-SDA-2026-04-26-gap | Age-Stratified Dosing Protocol Reflecting Endogenous Decline | 0.67 | 0.43 | AANAT; ASMT; MT1/MT2 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913 |
| h-SDA-2026-04-26-gap | CSF/Serum NfL Ratio Discriminates Active Transcytosis from Passive BBB Breakdown | 0.67 | 0.44 | NEFL, CAV1 | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260426-002803 |
| h-SDA-2026-04-26-gap | GFAP-Bearing Circulating Extracellular Vesicles Originating from Reactive Astroc | 0.67 | 0.52 | GFAP (Glial Fibrillary Acidic Protein) on brain-derived EVs | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260426-011448-7c85f5dc |
| h-fa7ac9cb | Oligodendrocyte DNA Repair Enhancement Therapy | 0.66 | 0.55 | PARP1 and XRCC1 | proposed | 2026-04-04 | SDA-2026-04-03-gap-seaad-v2-20260402032945 |
| h-5a55aabc | Complement C1q Subtype Switching | 0.66 | 0.55 | C1QA | debated | 2026-04-02 | sda-2026-04-01-gap-005 |
| h-771680d84f53 | Labile iron pool expansion amplifies genotype-specific ALS ferroptosis | 0.66 | 0.64 | FTL | proposed | 2026-04-26 | SDA-2026-04-26-gap-ferroptosis-mnd-768eaeba1be3 |
| h-b662ff65 | Stathmin-2 Splice Switching to Prevent Axonal Degeneration Across the ALS-FTD-AD | 0.66 | 0.90 | STMN2 (stathmin-2), PTBP1/PTBP2 | promoted | 2026-04-13 | SDA-2026-04-13-gap-20260410-172514 |
| h-538dfc70 | TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between SASP and Synaptic Pru | 0.66 | 0.58 | TNF, IL1B → GJA1 → C1Q/C3 | proposed | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113038-57244485 |
| h-5b0ebb1f | Choline Kinase Activity as Membrane Integrity Response Indicator | 0.66 | 0.30 | CHKA | proposed | 2026-04-16 | SDA-2026-04-04-gap-debate-20260403-222618-c698b06a |
| 32b2dd07-7c9a-416d-a | m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein Transcript and Prom | 0.66 | 0.45 | SNCA | open | 2026-04-27 | b7f886d9-da3f-4e0d-a8a8-9c262e268796 |
| h-fffd1a74 | RNA Granule Nucleation Site Modulation | 0.66 | 0.70 | G3BP1 | debated | 2026-04-02 | sda-2026-04-01-gap-006 |
| h-6c06ca11ee | Vascular Cell Type Crosstalk Driving Blood-Brain Barrier Breakdown | 0.66 | 0.58 | MMP9 | proposed | 2026-04-28 | SDA-2026-04-28-gap-methodol-20260427-041425-9e73b245 |
| h-f78f8262 | Pericyte-First Sequential Biomarker Cascade — Soluble PDGFR-β as Sentinel Event | 0.66 | 0.18 | PDGFRB | proposed | 2026-04-26 | SDA-2026-04-26-gap-bbb-permeability-biomarker-20260426 |
| h-7f2d0e21 | Peripheral-Central Immune Decoupling Therapy | 0.66 | 0.59 | TREM2, complement cascade components | proposed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |